Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate, which is in Phase 3 EASE trial for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 that is in preclinical stage for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.
IPO Year:
Exchange: NASDAQ
Website: amrytpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/6/2022 | $19.00 | Buy | Canaccord Genuity |
| 3/10/2022 | $20.00 → $18.00 | Buy | HC Wainwright & Co. |
| 3/10/2022 | $9.00 → $10.00 | Outperform | SVB Leerink |
| 11/23/2021 | $23.00 → $19.00 | Outperform | SVB Leerink |
| 10/4/2021 | $45.00 | Buy | JonesTrading |
| 8/19/2021 | $22.00 | Outperform | SVB Leerink |
| 8/19/2021 | $22.00 | Outperform | Cowen |
| 7/27/2021 | $29.00 | Buy | H.C. Wainwright |
SC 13G/A - Amryt Pharma plc (0001783010) (Subject)
SC 13G/A - Amryt Pharma plc (0001783010) (Subject)
SC 13G/A - Amryt Pharma plc (0001783010) (Subject)
SC 13G/A - Amryt Pharma plc (0001783010) (Subject)
SC 13G/A - Amryt Pharma plc (0001783010) (Subject)
SC 13G - Amryt Pharma plc (0001783010) (Subject)
SC 13G/A - Amryt Pharma plc (0001783010) (Subject)
SC 13G/A - Amryt Pharma plc (0001783010) (Subject)
SC 13G - Amryt Pharma plc (0001783010) (Subject)
SC 13G - Amryt Pharma plc (0001783010) (Subject)
● Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. PARMA, Italy, DUBLIN and BOSTON, MA, April 12, 2023 /PRNewswire/ -- Chiesi Farmaceutici S.p.A. ("Chiesi"), an international, research-focused biopharmaceuticals and healthcare group, today announced the completion of the acquisition of Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases. "We are excited to add the Amryt family to our company in this acquisition that demonstrates our commitment to ra
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. Parma Italy, Dublin Ireland and Boston MA, April 12, 2023 – Chiesi Farmaceutici S.p.A. ("Chiesi"), an international, research-focused biopharmaceuticals and healthcare group, today announced the completion of the acquisition of Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases. "We are excited to add the Amryt family to our comp
High Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3, 2023 Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases, is pleased to announce that the High Court of Justice of England and Wales (the "Court") has sanctioned the scheme of arrangement providing for the proposed acquisition (the "Transaction") of Amryt by Chiesi Farmaceutici S.p.A. ("Chiesi") at a hearing held on March 31, 2023. The parties expect the closing of the Transa
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici Transaction Expected to Close in Q2 2023 Dublin, Ireland, March 22, 2023 Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases, is pleased to announce that all resolutions presented to shareholders at today's shareholder meetings held to consider and vote on the proposed acquisition of Amryt by Chiesi Farmaceutici S.p.A., (the "Transaction") were duly passed. The full text of each resolution was included in the notice of the shareholder meetings posted to shareholders on Febr
AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023 Dublin, Ireland, February 16, 2023 Amryt Pharma Plc ("Amryt") (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases, announced today that it has published a scheme circular (the "Scheme Circular") to its shareholders regarding the Amryt shareholder meetings to be held to consider and vote on the proposed acquisition of Amryt (the "Transaction") by Chiesi Farmaceutici S.p.A., an Italian società per azioni. As set forth in the Scheme Circula
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc - Transaction expands Chiesi's rare disease medicine portfolio - All cash acquisition at US$14.50 per ADS, plus Contingent Value Rights of up to an additional US$2.50 per ADS based on certain Filsuvez® milestones being achieved - Total Transaction value of up to US$1.48 Billion with upfront consideration representing a 107% premium to Amryt ADS' closing price on January 6, 2023 - Transaction unanimously approved and recommended by the Boards of both Chiesi and Amryt - Transaction supported by voting agreements from leading Amryt shareholders and directors - Transaction exp
Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH DUBLIN, Ireland, and Boston MA, January 5, 2023, Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce positive results from its APH-19 Phase 3 trial of lomitapide for the treatment of Homozygous Familial Hypercholesterolemia (HoFH) in children aged 5-17 years. Dr Joe Wiley, CEO of Amryt Pharma, commented: "We are encouraged by these important additional results regarding the efficacy of lomitapide in treating children with HoFH. This is good news for patients and th
COMP Adopts Positive Opinion on Orphan Designation for Mycapssa® for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors DUBLIN, Ireland, and Boston MA, December 19, 2022 Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion for orphan designation for the use of Mycapssa® in the treatment of carcinoid syndrome associated with neuroendocrine tumors (NET). Orphan designation in the European Union (EU) is granted by the Europe
European Commission approves Mycapssa® for the treatment of Acromegaly Mycapssa® will be the first and only oral somatostatin analog approved in the EU Approval based on MPOWERED Phase 3 trial DUBLIN, Ireland, and Boston MA, December 5, 2022, Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce the European Commission (EC) approval of Mycapssa® in the European Union (EU) for the maintenance treatment of acromegaly in patients who have responded to and tolerated treatment with octreotide or lanreotide. Mycapssa® is already approved in the United States for
Amryt Announces New Patent for Mycapssa® DUBLIN, Ireland, and Boston MA, November 30, 2022 Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces an update regarding the patents for its product Mycapssa® (octreotide). Mycapssa®The USPTO has issued to Amryt US Patent No. 11,510,963, with claims related to the Mycapssa® product. This patent will expire in February 2036. With the addition of this patent, Amryt has ten Orange Book-listed patents for Mycapssa® with patent protection through December 2040. Dr Joe Wiley, CEO of Amryt Pharma, commented: "We are always worki
Canaccord Genuity resumed coverage of Amryt Pharma plc with a rating of Buy and set a new price target of $19.00
HC Wainwright & Co. reiterated coverage of Amryt Pharma with a rating of Buy and set a new price target of $18.00 from $20.00 previously
SVB Leerink reiterated coverage of Amryt Pharma with a rating of Outperform and set a new price target of $10.00 from $9.00 previously
SVB Leerink reiterated coverage of Amryt Pharma with a rating of Outperform and set a new price target of $19.00 from $23.00 previously
JonesTrading initiated coverage of Amryt Pharma with a rating of Buy and set a new price target of $45.00
SVB Leerink initiated coverage of Amryt Pharma plc with a rating of Outperform and set a new price target of $22.00
Cowen initiated coverage of Amryt Pharma plc with a rating of Outperform and set a new price target of $22.00
H.C. Wainwright initiated coverage of Amryt Pharma plc with a rating of Buy and set a new price target of $29.00
Maxim Group initiated coverage of Amryt Pharma with a rating of Buy and set a new price target of $27.00
SVB Leerink resumed coverage of Amryt Pharma with a rating of Buy and set a new price target of $40.00
Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer DUBLIN, Ireland, and Boston MA, June 27, 2022, Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce the appointment of Dr Tracy Cunningham as Chief Medical officer (CMO) with immediate effect. Dr Cunningham joined Amryt in April 2020 as VP, Head of Development with responsibility for pre-clinical and clinical development of the Amryt portfolio. Prior to this, she held senior regional and global leadership roles in AstraZeneca, Novartis and GlaxoSmithKine. She is a graduate of the Roya
DUBLIN, Ireland, and Boston MA, April 6, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce the appointment of Sheila Frame as President Americas. Sheila will lead all aspects of product commercialization for Amryt in the Americas. Sheila has held senior leadership roles across several specialty areas with Novartis, Bristol-Myers Squibb, UCB, and AstraZeneca and has worked and lived in North America and in Europe. Sheila holds an MBA from Concordia University. Dr Joe Wiley, CEO of Amryt Pharma, commented: “Sheila is a very experienced
EFFECT - Amryt Pharma plc (0001783010) (Filer)
15F-12B - Amryt Pharma plc (0001783010) (Filer)
EFFECT - Amryt Pharma plc (0001783010) (Filer)
EFFECT - Amryt Pharma plc (0001783010) (Filer)
POS AM - Amryt Pharma plc (0001783010) (Filer)
POS AM - Amryt Pharma plc (0001783010) (Filer)
POS AM - Amryt Pharma plc (0001783010) (Filer)
6-K - Amryt Pharma plc (0001783010) (Filer)
25-NSE - Amryt Pharma plc (0001783010) (Subject)
6-K - Amryt Pharma plc (0001783010) (Filer)
Amryt Reports Q3 2022 Financial and Operational Results 8.2% YoY revenue growth in Q3 to $61.1M - 12.5% on a constant currency basis 11th consecutive quarter of positive EBITDA generation; $12.5M in Q3 2022 Operating cash flows of $14.3M for Q3 2022 Cash of $83.4M at September 30, 2022 Mycapssa® revenues increased 26.9% QoQ to $5.7M and 292.8% YoY CHMP positive opinion for Mycapssa® for the treatment of acromegaly in the EU Pathway agreed with the FDA to initiate a Phase 3 study for NET - expected in Q1 2023 Filsuvez® European launch progressing well Significant metreleptin LATAM $8.3M tender won - revenue expected to be recognized in Q4 Reaffirming FY 2022 revenue guidance to $26
Amryt to Report Q3 2022 Results on November 3, 2022 DUBLIN, Ireland, and Boston MA, October 19, 2022, Amryt (NASDAQ:AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that its unaudited financial results for the third quarter 2022 will be released on Thursday, November 3, 2022 at 0700 ET/1100 GMT. Amryt will host a conference call and webcast for analysts and investors on November 3, 2022 at 0830 ET/1230 GMT. Webcast Player URL: https://edge.media-server.com/mmc/p/6nxxorrj Telephone Dial in details: Standard International Number + 39 (0) 02 802 0911 United States +1
Amryt Reports Record Q2 2022 Results 9.2% YoY revenue growth in Q2 to $68.5M 35.3% YoY revenue growth in Q2 excluding impact of a sporadic LATAM order in Q2 2021 7.8% growth in metreleptin revenues YoY to $46.4M in Q2 49.9% growth in metreleptin revenues in Q2 excluding impact of a sporadic LATAM order in Q2 2021 10th consecutive quarter of positive EBITDA generation Cash of $90.7M at June 30, 2022 Filsuvez® approved in the EU for the treatment of dystrophic and junctional EB Amryt now has four growing commercial products treating rare diseases Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Stock repurchase program underway
DUBLIN, Ireland, and Boston MA, July 21, 2022, Amryt (NASDAQ:AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that its unaudited financial results for the second quarter 2022 will be released on Thursday, August 4, 2022 at 0700 ET/1200 BST. Amryt will host a conference call and webcast for analysts and investors on August 4, 2022 at 0830 ET/1330 BST. Webcast Player URL: https://edge.media-server.com/mmc/p/ef7uj5u8 Telephone Dial in details: United States +1 646 307 1963United Kingdom +44 (0) 203 481 4247Ireland +353 (1) 582 2023Confirmation Code9953783 A playback facility
Amryt Reports Record Q1 2022 Results CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EB Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Board approved stock repurchase program of up to $30M Cash of $102.2M at March 31, 2022 22.1% YoY revenue growth in Q1 to $59.1M 25.7% growth in metreleptin revenues YoY to $37.6M in Q1 9th consecutive quarter of positive EBITDA generation Successful bioavailability study supporting development of Mycapssa® for carcinoid symptoms in NET Conference call and webcast today at 0830 ET / 1330 BST DUBLIN, Ireland, and Boston MA, May 4, 2022, Amryt (NASDAQ:AMYT), a global, c
Amryt to Report Q1 2022 Results on May 4, 2022 DUBLIN, Ireland, and Boston MA, April 14, 2022, Amryt (NASDAQ:AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that its unaudited financial results for the first quarter 2022 will be released on Wednesday, May 4, 2022 at 0700 ET/1200 BST. Amryt will host a conference call and webcast for analysts and investors on May 4, 2022 at 0830 ET/1330 BST. Webcast Player URL: https://edge.media-server.com/mmc/p/uso54daj Telephone Dial in details: United States +1 646 741 3167 United Kingdom +44 (0) 207 192 8338 Ireland +353 (1
Amryt Announces 22% growth in FY 2021 Revenues to $222.5M Issuing FY 2022 revenue guidance of $260M - $270M, representing 17%-21% YoY growth Cash of $113.0M at December 31, 2021 Board approves stock repurchase program of up to $30M 8th consecutive quarter of positive EBITDA generation 32% YoY growth in metreleptin revenues Successful bioavailability study supporting development of Mycapssa® for carcinoid symptoms in NET Global NET market opportunity is estimated to be approx. $1.9bn* Conference call and webcast today at 0830 EST / 1330 GMT DUBLIN, Ireland, and Boston MA, March 9, 2022, Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring
Amryt to Report FY and Q4 2021 Results on March 9, 2022 DUBLIN, Ireland, and Boston MA, February 23, 2022, Amryt (NASDAQ:AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that its unaudited financial results for the fourth quarter 2021 and full year ended December 31, 2021 will be released on Wednesday, March 9, 2022 at 0700 EST / 1200 GMT. Amryt will host a conference call and webcast for analysts and investors on March 9 at 0830 EST / 1330 GMT. Webcast Player URL: https://edge.media-server.com/mmc/p/ebranod7 Telephone Dial in details: United States +1 646 741 3
Amryt Reports Record Q1 2021 Financial and Operating Results 8.7% YoY revenue growth in the quarter to $48.4M 16.5% YoY underlying revenue growth excluding the impact of a LATAM periodic order in Q1 2020 5th consecutive quarter of positive EBITDA generation National reimbursement achieved for metreleptin in England, Wales and France Regulatory submissions for Oleogel-S101 (Filsuvez®) made to the FDA and EMA Raising FY 2021 revenue guidance to $205M - $210M Today announced proposed acquisition of Chiasma, Inc. (NASDAQ:CHMA) Conference call and webcast today at 0830 EDT / 1330 BST DUBLIN, Ireland, and Boston MA, May 5, 2021, Amryt (NASDAQ:AMYT, AIM: AMYT))), a global, commercial-stag